Senti Biosciences, Inc. SNTI

Senti Biosciences Holdings, Inc. announced a strategic transaction to unlock value for its gene-circuit-enabled pipeline including SENTI-202 and to sharpen focus on next-generation controllable genetic medicines powered by its Regulator Dial™ Technology Platform. Major strategic transaction unlocks pipeline value and refocuses company on core technology platform.

Senti Biosciences announces positive FDA RMAT meeting confirming registrational clinical and CMC strategy for SENTI-202 in relapsed/refractory AML, plus important efficacy and durability updates from the SENTI-202 program. Positive FDA RMAT meeting and efficacy/durability data for SENTI-202 provide clear path to registration in AML, fundamentally transforming Senti Biosciences' competitive position and long-term prospects.

Senti Biosciences Holdings reports first quarter 2026 financial results and advances SENTI-202 program into pivotal phase. Advancement of SENTI-202 into pivotal phase marks a major clinical milestone that could significantly enhance competitive positioning and investor sentiment.

Senti Biosciences announces publication in Cell Systems demonstrating advanced logic-gated CAR design enabling precise control in cell therapies. Publication in prestigious Cell Systems validates innovative logic-gated CAR technology, likely boosting Senti's pipeline credibility and investor sentiment.

Senti Biosciences, Inc. (SNTI) reported fourth quarter and full year 2025 financial results alongside a corporate update. Financial results disclosure affects key financial performance metrics and investor sentiment without transformative shifts.

Senti Biosciences, Inc. (SNTI) will present clinical and translational data on SENTI-202 at the 11th Annual Innate Killer Conference. Presentation of clinical data on SENTI-202 signals pipeline progress but impact depends on data quality and market reception.

Senti Biosciences, Inc. has completed enrollment in its Phase 1 clinical trial for SENTI-202, aimed at treating relapsed or refractory acute myeloid leukemia (R/R AML). This milestone marks a significant step in the development of the therapy, which utilizes engineered cell therapies to target cancer cells more effectively. The trial's completion is expected to provide critical data on the safety and efficacy of SENTI-202, potentially advancing treatment options for patients with R/R AML. Completion of enrollment in a Phase 1 clinical trial for a targeted cancer therapy is a significant step that could influence future product development and market positioning.

Senti Biosciences, Inc. has been selected for an on-stage presentation at the Healthcare Conference Taipei 2026, highlighting its innovative approaches in the biotechnology sector. This opportunity is expected to enhance the company's visibility and engagement with potential investors and partners in the healthcare industry. The presentation at a significant healthcare conference may enhance visibility and networking opportunities, potentially influencing future partnerships and market sentiment.

Senti Biosciences, Inc. participated in a virtual investor segment to present its innovative data on acute myeloid leukemia (AML) at the American Society of Hematology Annual Meeting. The company also announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation, which could expedite the development of its AML therapies. The RMAT designation and presentation of groundbreaking AML data are likely to significantly impact Senti Biosciences' future performance and investor sentiment.

Senti Biosciences, Inc. will participate in a panel presentation at the Biotech Showcase, coinciding with the J.P. Morgan Annual Healthcare Conference. This event is a significant platform for biotech companies to showcase their innovations and engage with investors and industry leaders. Participation in high-profile industry events can enhance visibility and networking opportunities, potentially influencing market sentiment and investor interest.

Senti Biosciences, Inc. has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its product SENTI-202, aimed at treating adults with relapsed or refractory acute myeloid leukemia. This designation is expected to expedite the development and review process for the therapy, potentially enhancing treatment options for patients with this challenging condition. The RMAT designation is a significant regulatory milestone that could accelerate the development and market introduction of a promising therapy, impacting Senti's future performance.

Senti Biosciences, Inc. announced updated clinical data from its ongoing Phase 1 trial of SENTI-202 in patients with relapsed or refractory acute myeloid leukemia. The results show deep, minimal residual disease (MRD) negative, durable complete remissions alongside a favorable safety profile, indicating promising therapeutic potential for this patient population. The demonstration of durable complete remissions and a favorable safety profile could significantly enhance Senti Biosciences' competitive positioning and investor sentiment.

Senti Biosciences, Inc. (SNTI) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company's operations or strategic initiatives. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Senti Biosciences, Inc. will host a conference call and webcast on December 9th at 8:00 AM ET to discuss clinical data for SENTI-202, which will be presented at the American Society of Hematology (ASH) Annual Meeting 2025. The presentation of clinical data at a major conference may influence investor sentiment and provide insights into product development.

Senti Biosciences, Inc. reported its financial results for the third quarter of 2025 and confirmed that the next clinical data readout for its Phase 1 SENTI-202 study in Acute Myeloid Leukemia (AML) will take place at the American Society of Hematology Annual Meeting in December. The upcoming clinical data readout is a significant event that could influence investor sentiment and the company's future trajectory.

Senti Biosciences, Inc. will present updated clinical results for its first-in-class Logic Gated CD33/FLT3 cell therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting in 2025. This presentation is expected to provide insights into the therapy's efficacy and safety profile, potentially influencing future development and investment interest. The presentation of updated clinical results for a novel therapy could significantly impact investor sentiment and the company's strategic direction.

Senti Biosciences, Inc. will present at Chardan's 9th Annual Genetic Medicines Conference, highlighting its advancements in genetic medicine and potential innovations in the field. The event will provide a platform for Senti Bio to showcase its research and development efforts to investors and industry peers. Participation in significant industry conferences can enhance visibility and attract potential investment opportunities.

Senti Biosciences, Inc. will present at BioJapan, highlighting its advancements in gene circuit technology and its applications in cell and gene therapies. The presentation aims to showcase the company's innovative approaches and potential collaborations in the biopharmaceutical sector. Participation in BioJapan could enhance visibility and networking opportunities, potentially influencing future collaborations and market sentiment.

Senti Biosciences, Inc. will present at the MedInvest Biotech & Pharma Conference, highlighting its advancements in gene circuit technology and potential applications in cell and gene therapies. The conference serves as a platform for Senti Bio to engage with investors and industry leaders, showcasing its innovative approaches to treating diseases. Participation in the conference may enhance investor interest and visibility, but the overall impact on the company's trajectory is expected to be limited.

Senti Biosciences, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its advancements in synthetic biology and cell therapy. The conference is a platform for the company to engage with investors and showcase its innovative approaches in the biotech sector. Participation in significant investment conferences can enhance visibility and investor interest, potentially influencing market sentiment.

Senti Biosciences, Inc. participated in a virtual investor segment discussing the Phase 2 dose and schedule selection for its clinical trial of SENTI-202, aimed at treating Acute Myeloid Leukemia. The discussion highlighted the significance of the trial's design and its potential implications for patient outcomes. The Phase 2 trial's design and outcomes could significantly influence Senti Biosciences' market position and investor sentiment.

Senti Biosciences, Inc. reported its financial results for the second quarter of 2025, highlighting progress in its Phase 1 SENTI-202 study targeting Acute Myeloid Leukemia (AML). The company confirmed that the next data milestone for this study is expected in the fourth quarter of 2025. The upcoming data milestone for the SENTI-202 study could moderately influence investor sentiment and the company's competitive positioning in the oncology market.

Senti Biosciences, Inc. has identified the Recommended Phase 2 Dose (RP2D) for its SENTI-202 therapy in a Phase 1 clinical study targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia. This milestone is a significant step in the development of SENTI-202, which aims to improve treatment outcomes for patients with these challenging conditions. Determining the RP2D is a critical advancement that could significantly influence the drug's development and market potential.

Senti Biosciences, Inc. (Nasdaq: SNTI) announced that CEO Timothy Lu participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference, discussing his commitment to the company and its development programs. The on-demand video is available on virtualinvestorco.com and Senti Bio's website. Senti Bio focuses on next-generation cell and gene therapies using its Gene Circuit platform to target incurable diseases, with a pipeline aimed at challenging tumor indications. Participation in investor conferences can enhance visibility and investor sentiment, potentially influencing market performance.

Kanya Rajangam, M.D., Ph.D., Chief Medical Officer of Senti Biosciences, Inc. (SNTI), is scheduled to deliver a feature presentation at the BioScience Forum. The event will focus on advancements in the field of synthetic biology and Senti's innovative approaches to developing therapies. The presentation may enhance visibility and interest in Senti's therapeutic innovations, potentially influencing market sentiment.

Senti Biosciences, Inc. has appointed Bryan Baum, a serial entrepreneur and investor, to its Board of Directors. Baum, Co-Founder and Managing Partner of K5 Global, brings extensive experience from his investments in companies like SpaceX and OpenAI. CEO Timothy Lu expressed confidence in Baum's expertise to help advance Senti's Gene Circuit platform, which aims to develop innovative cell and gene therapies for cancer treatment. Baum highlighted the potential of Senti's Logic Gated cell therapies to transform cancer treatments. He has a history of founding and selling successful ventures and has made over 200 angel investments. The appointment of a high-profile investor and entrepreneur like Bryan Baum is likely to significantly enhance Senti Bio's strategic direction and market positioning.

Senti Biosciences, Inc. (Nasdaq: SNTI) announced that CEO Timothy Lu participated in Nasdaq's Amplify Spotlight Series, discussing the company's proprietary Gene Circuit platform for developing cell and gene therapies. The lead program, SENTI-202, is a CAR NK cell therapy targeting hematologic malignancies like AML and MDS, currently in a Phase 1 trial with positive preliminary data. SENTI-202 has received Orphan Drug Designation from the FDA for treating relapsed/refractory hematologic malignancies. Senti Bio's advancements in its lead therapy and FDA designation could significantly enhance its market position and investor sentiment.

Senti Biosciences, Inc. (SNTI) is set to present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference. The event will showcase advancements in synthetic biology, highlighting Senti Bio's contributions and innovations in the field. This presentation aims to enhance the company's visibility and engagement with industry leaders and researchers. Participation in a prominent conference may enhance Senti Bio's visibility and networking opportunities, potentially influencing its market position.

Senti Biosciences, Inc. has received U.S. FDA Orphan Drug Designation for its innovative SENTI-202 therapy, which utilizes off-the-shelf logic gated selective CAR NK cell therapy targeting CD33 or FLT3 NOT EMCN to treat Acute Myeloid Leukemia. This designation is expected to expedite the development and regulatory review process for the therapy, potentially enhancing treatment options for patients with this aggressive form of cancer. The FDA Orphan Drug Designation is a significant regulatory milestone that could accelerate the development and market entry of SENTI-202, impacting Senti Biosciences' future performance.

Senti Biosciences, Inc. (Nasdaq: SNTI) will participate in a Virtual Fireside Chat hosted by Chardan Capital Markets on June 9, 2025, at 3:00 PM ET. Key executives, including CEO Timothy Lu and CMO Kanya Rajangam, will discuss the company's innovative Gene Circuit platform, which aims to develop advanced cell and gene therapies targeting incurable diseases. Senti Bio focuses on creating therapies that precisely target cancer cells while sparing healthy cells, with a pipeline addressing both liquid and solid tumors. The company also explores applications of its Gene Circuits beyond oncology through partnerships. The event may influence investor sentiment and provide insights into Senti Bio's strategic direction and product development.